Amantadine: Phase II data

Top-line data from 56 MS patients with walking impairment in the modified intent-to-treat

Read the full 131 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE